To determine the efficiency of our approach, we assessed the percentage of DMD patients reported in the LOVD-DMD registry that would be identified by our assay and would be rescuable by either exon-51, exon-53 or exon-45 skipping therapy (Fig. 1B). Here, DMD is linked to Duchenne muscular dystrophy.